Researches on the polymorphism of cytochrome P450 2A6

Chinese Journal of Medical Genetics

Volumn 19, Issue 5, 2002, Pages 424-427

  Tong, Ziying ^a   Zhuge, Jian ^a   Yu, Yingnian ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Allele; Cytochrome P450 2A6; Genetic polymorphism

Indexed keywords

BIOLOGICAL ORGANS; ENZYMES; OXIDATION; TUMORS;

POLYMORPHISM; SMOKING BEHAVIOR;

GENETIC ENGINEERING;

CYTOCHROME P450 2A6;

ALLELISM; CANCER SUSCEPTIBILITY; CIGARETTE SMOKING; ENZYME ACTIVITY; ESOPHAGUS CARCINOMA; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; LUNG CARCINOMA; OXIDATION; REVIEW; SMOKING HABIT;

ARYL HYDROCARBON HYDROXYLASES; ESOPHAGEAL NEOPLASMS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LUNG NEOPLASMS; MIXED FUNCTION OXYGENASES; POLYMORPHISM, GENETIC; RESEARCH; SMOKING;

EID: 0036800594     PISSN: 10039406     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (25)

1. Ingelman-Sundberg M, Oscarson M, McLellan RA. Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment. Trends Pharmacol Sci, 1999, 20: 342-349.
2. Oscarson M, Gullsten H, Rautio A, et al. Genotyping of human cytochrome P450 2A6 (CYP2A6), a nicotine C-oxidase. FEBS Lett, 1998, 438, 201-205.
3. Hoffman SM, Fernandez-Salguero P, Gonzalez FJ, et al. Organization and evolution of the cytochrome P450 CYP2A-2B-2F subfamily gene cluster on human chromosome 19. J Mol Evol, 1995, 41: 894-900.
4. Rao Y, Hoffmann E, Zia M, et al. Duplications and defects in the CYP2A6 gene: identification, genotyping, and in vivo effects on smoking. Mol Pharmacol, 2000, 58: 747-755.
5. Yamano S, Tatsuno J, Gonzalez FJ. The CYP2A3 gene product catalyzes coumarin 7-hydroxylation in human liver microsomes. Biochemistry, 1990, 29: 1322-1329.
6. Fernandez-Salguero P, Hoffman SM, Cholerton S, et al. A genetic polymorphism in coumarin 7-hydroxylation: sequence of the human CYP2A genes and identification of variant CYP2A6 alleles. Am J Hum Genet, 1995, 57: 651-660.
7. Shimada T, Yamazaki H, Guengerich FP. Ethnic-related differences in coumarin 7-hydroxylation activities catalyzed by cytochrome P450 2A6 in liver microsomes of Japanese and Caucasian populations. Xenobiotica, 1996, 26: 395-403.
8. Nunoya K, Yokoi T, Kimura K, et al. A new deleted allele in the human cytochrome P450 2A6 (CYP2A6) gene found in individuals showing poor metabolic capacity to coumarin and (+)-cis-3, 5-dimethyl-2-(3-pyridyl) thiazolidin-4-one hydrochloride (SM-12502). Pharmacogenetics, 1998, 8: 239-249.
9. Nunoya K, Yokoi T, Takahashi Y, et al. Homologous unequal cross-over within the human CYP2A gene cluster as a mechanism for the deletion of the entire CYP2A6 gene associated with the poor metabolizer phenotype. J Biochem (Tokyo), 1999, 126: 402-407.
10. Oscarson M, McLellan RA, Gullsten H, et al. Characterisation and PCR-based detection of a CYP2A6 gene deletion found at a high frequency in a Chinese population. FEBS Lett, 1999, 448: 105-110.
11. Oscarson M, McLellan RA, Gullsten H, et al. Identification and characterisation of novel polymorphisms in the CYP2A locus: implications for nicotine metabolism. FEBS Lett, 1999, 460: 321-327.
12. Zhuge J, Qian YL, Xie HY, et al. Cloning of a new human cytochrome P450 2A6 cDNA. Chin J Pathophysiol, 2000, 16: 875-878
13. Yan LQ, Yu YN, Zhuge J, et al. Cloning of human cytochrome P450 2A6 cDNA and its expression in mammalian cells. Chin J Pharmacol Toxicol, 2000, 14: 31-35
14. Miyamoto M, Umetsu Y, Dosaka-Akita H, et al. CYP2A6 gene deletion reduces susceptibility to lung cancer. Biochem Biophys Res Commun, 1999, 261: 658-660.
15. Kitagawa K, Kunugita N, Kitagawa M, et al. CYP2A6 * 6, a novel polymorphism in cytochrome P450 2A6, has a single amino acid substitution (R128Q) that inactivates enzymatic activity. J Biol Chem, 2001, 276: 17830-17835.
16. Ariyoshi N, Sawamura Y, Kamataki T. A novel single nucleotide polymorphism altering stability and activity of CYP2A6. Biochem Biophys Res Commun, 2001, 281: 810-814.
17. Pitarque M, von Richter O, Oke B, et al. Identification of a single nucleotide polymorphism in the TATA box of the CYP2A6 gene: impairment of its promoter activity. Biochem Biophys Res Commun, 2001, 284: 455-460.
18. Xu C, Rao YS, Xu B, et al. An in vivo pilot study characterizing the new CYP2A6 * 7, * 8, and * 10 alleles. Biochem Biophys Res Commun, 2002, 290: 318-324.
19. Messina ES, Tyndale RF, Sellers EM. A major role for CYP2A6 in nicotine C-oxidation by human liver microsomes. J Pharmacol Exp Ther, 1997, 282: 1608-1614.
20. Murphy SE, Johnson LM, Pullo DA. Characterization of multiple products of cytochrome P450 2A6-catalyzed cotinine metabolism. Chem Res Toxicol, 1999, 12: 639-645.
21. Kitagawa K, Kunugita N, Katoh T, et al. The significance of the homozygous CYP2A6 deletion on nicotine metabolism: a new genotyping method of CYP2A6 using a single PCR-RFLP. Biochem Biophys Res Commun, 1999, 262: 146-151.
22. Pianezza ML, Sellers EM, Tyndale RF. Nicotine metabolism defect reduces smoking. Nature, 1998, 393: 750.
23. Sellers EM, Kaplan HL, Tyndale RF. Inhibition of cytochrome P450 2A6 increases nicotine's oral bioavailability and decreases smoking. Clin Pharmacol Ther, 2000, 68: 35-43.
24. Loriot MA, Rebuissou S, Oscarson M, et al. Genetic polymorphisms of cytochrome P450 2A6 in a case-control study on lung cancer in a French population. Pharmacogenetics, 2001, 11: 39-44.
25. Anderson LM, Chhabra SK, Nerurkar PV, et al. Alcohol-related cancer risk: a toxicokinetic hypothesis. Alcohol, 1995, 12: 97-104.